Update from our Patient Experience Survey:

9541 respondents

95% adults, 5% children (parents responded on their child’s behalf)

25% with rheumatoid arthritis
20% systemic lupus erythematosus
9% Sjogren’s syndrome
7% ankylosing spondylitis 465 patients reported COVID-19 diagnoses (about 5% of respondents)

159 dx themselves based on symptoms
122 dx by a physician based on symptoms
55 dx by a physician based on laboratory tests
87 other (e.g. exposure to a case, presence of symptoms but negative testing, etc.)

CORRECTED THREAD: from the Global Provider-entered Registry (EULAR registry not included)

Total = 146 patients; 23% are male/77% female, 18% are age 65+.

7 patients are deceased.

Top 3 COVID symptoms: 75% cough, 73% fever, 52% shortness of breath; 37% had all three of these Top 5 conditions: 36% Rheumatoid Arthritis, 17% Lupus, 10% Psoriatic Arthritis, 8% Ankylosing Spondylitis, 8% Sjogren’s

69% on conventional DMARD (25% on hydroxychloroquine), 39% on biologic DMARD, 5% on JAKi

31% on glucocorticoids, 27% on NSAIDs

THREAD: Update on the @rheum_covid / rheum-covid.org provider registries:

We now have 110 patients in our registries (EULAR + Global). Approximately 70% are female, and 18% are over the age of 65. Most patients in the registry have RA (36%), followed by PsA (17%), and SLE (17%).

A majority of patients were on conventional synthetic DMARDs prior to diagnosis (63%), almost half on biologics (45%); a quarter were on glucocorticoids, and a quarter on NSAIDS.

THREAD:

Initial data from the first 47 validated cases in the Global Registry Most have RA (38%), SLE (17%) and PsA (11%). 75% of patients were in remission or had low disease activity at the time of infection.